ClearPoint Neuro price target raised to $15 from $11 at Lake Street

Lake Street raised the firm’s price target on ClearPoint Neuro (CLPT) to $15 from $11 and keeps a Buy rating on the shares after the company announced the early repayment of its $10M PTC Therapeutics (PTCT) convertible note. Given the early repayment and $6 per share strike, the company is forgoing a 6% share dilution with the early repayment and ClearPoint also indicated the partnership with PTC for the development of Upstaza remains unchanged, noted the analyst.